Brief: Glenmark Life Sciences Expects GPL Business To Remain Steady In Coming Quarters
April 27 (Reuters) - Glenmark Life Sciences Ltd
GLEM.NS :
* EXPECT GPL BUSINESS TO REMAIN STEADY IN COMING QUARTERS
* EXTERNAL BUSINESS WAS DRIVEN BY STRONG GROWTH IN US,
LATAM, AND
JAPAN
Source text for Eikon: ID:nBSE3HCg6x
Further company coverage: GLEM.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alivus Life Sciences
See all newsBrief: Alivus Life Sciences Incorporates Subsidiary Alivus Life Sciences Do Brasil Ltda In Brazil
Brief: Alivus Life Sciences To Buy 76% Stake In Iqgen-X Pharma For Approx 91.2 Million Rupees
India's Alivus rises to 15-month high as brokerages optimistic about drugmaker's annual outlook
India's Alivus Life Sciences rises after quarterly profit increase
Brief: Alivus Life Sciences Ltd March-Quarter Profit 1.63 Billion Rupees